Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: tisotumab vedotin | 0.60 |
| trials ClinicalTrials.gov | 12 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 66 Parkinson's papers of 16,237 | 0.45 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5704
Sealed predictions
- F3 in dopamine neurons, braak+0.26 (p 0.493) → -0.21 (p 0.586)receipt 5711
Swarm cases
receipt 5711: F3 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.894, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.13, sign flips 6; without severely affected donors -0.01 (p 0.983, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.59 (p 0.0099, n 18) vs -0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for F3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up F3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.68 p 0.016 (needs p < 3.5e-4)
Receipts
loading the receipts